SciSparc & Clearmind Patent for Ibogaine Therapy
Ticker: SPRC · Form: 6-K · Filed: Sep 16, 2024 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Sep 16, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: patent, collaboration, pharmaceuticals, drug-development
TL;DR
SciSparc and Clearmind just published an international patent for an Ibogaine combo therapy for addiction. Big step for new treatments.
AI Summary
On September 16, 2024, SciSparc Ltd. announced the publication of an international patent application for a pioneering Ibogaine combination therapy. This collaboration with Clearmind Medicine focuses on developing novel treatments for substance abuse disorders.
Why It Matters
This patent application signifies progress in developing new therapeutic approaches for substance abuse, potentially offering novel treatment options.
Risk Assessment
Risk Level: medium — The filing concerns a patent application, which is an early stage of development and does not guarantee commercial success or regulatory approval.
Key Players & Entities
- SciSparc Ltd. (company) — Filer of the report and collaborator
- Clearmind Medicine (company) — Collaborator on the patent application
- September 16, 2024 (date) — Date of the press release
- Ibogaine (drug) — Key component of the patented therapy
FAQ
What is the specific focus of the international patent application filed by SciSparc and Clearmind Medicine?
The patent application is for a pioneering Ibogaine combination therapy aimed at treating substance abuse disorders.
When was the press release announcing this patent application issued?
The press release was issued on September 16, 2024.
What is the relationship between SciSparc Ltd. and Clearmind Medicine in this context?
They are collaborators who jointly announced the publication of the international patent application.
What type of therapy does the patent application relate to?
The patent application relates to an Ibogaine combination therapy.
Under which US securities act is this Form 6-K filed?
This Form 6-K is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Filing Stats: 321 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2024-09-16 16:15:27
Filing Documents
- ea0214632-6k_scisparc.htm (6-K) — 12KB
- ea021463202ex99-1_scisparc.htm (EX-99.1) — 10KB
- 0001213900-24-078972.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: September 16, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3